Research on chimeric antigen receptor macrophages (CAR-M) is being conducted to explore its potential in treating solid tumors, particularly those that are HER2 positive. Studies are investigating the use of CAR-M in combination with PD1 blockade, with some focusing on programming and engineering strategies for cancer immunotherapy. The field appears to be actively advancing, with various approaches being developed and tested in pre-clinical models and potentially for use in cancers such as prostate cancer.